Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Opdivo (Nivolumab) for the Treatment of Unresectable or Metastatic Melanoma

Drug Name (Brand / Generic)

Opdivo / Nivolumab

Developed by

Bristol-Myers Squibb (BMS)

Therapy Class

Human immunoglobulin G4 (IgG4) monoclonal antibody

Current Indications

Unresectable or Metastatic Melanoma, small cell lung cancer (SCLC), non-SCLC, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma

Market Sector

Oncology

Development Status

Approved in the US, Europe, and Taiwan
Expand
Close
Close
Close

Go Top